CFDA approves Gilead ’s Sovaldi for chronic hepatitis C treatment

The China Food and Drug Administration (CFDA) has approved Gilead Sciences ’ Sovaldi (sofosbuvir at 400mg) for the treatment of patients with chronic hepatitis C virus (HCV) infection.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news